Financial boost for BioVersys’ R&D on anti-bacterial resistance drugs

The global non-profit partnership CARB-X (Combating Antibiotic- Resistant Bacteria Biopharmaceutical Accelerator) is supporting the D-BSSE spin-off BioVersys with an award of up to $15.34 Million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics targeting specific drug-resistant bacteria.